Kornimate/medical-research-clean huggingface dataset:
intermittent suction technique in the diagnosis of pancreatic solid lesions

Conditions: Pancreatic Cancer; Pancreatic Neoplasms

Summary: the aim of this study is to compare the diagnostic yield of intermittent versus continuous suction in the diagnosis of pancreatic solid lesions.

solid lesions of the pancreas can be neoplastic or non neoplastic and it is important to accurately differentiate between them because of the poor prognosis related to pancreatic neoplasm. there are many types of solid pancreatic lesions: pancreatic adenocarcinoma, neuroendocrine tumor, lymphoma, solid pseudopapillary neoplasm and pancreatic metastasis. there are several diagnostic methods for the study of pancreatic solid lesions. the different imaging test allow detection and characterization of those lesions, but most times an anatomopathological diagnosis is needed before stablishing the most appropriate treatment. endoscopic ultrasound guided fine needle aspiration (eus-fna) is the diagnostic method of choice for the diagnosis of these lesions as it detects small lesions that sometimes cannot be found in radiological imaging test, evaluates vascular invasion and the presence of liver metastasis, and allows pancreatic puncture for a cytological diagnosis. eus-fna is the safest technique for pancreatic puncture and the least related to needle track seeding. in order to gather as much material as possible different techniques have been proposed: * fanning technique and multiple pass technique: to guide the needle into different regions of the target lesions with or without removing the needle out of the lesion depending on wether the lesion is hard or soft. * use of stylet: there are no data clearly demonstrating that the use of suction increases the yield of eus-fna. some authors do slow withdrawal of the stylet. * size of the needle: 19 gauge, 22 gauge, 25 gauge, depending on the localization, size and vascularization. there is increasing evidence that smaller needles offer at least similar results in diagnostic yield compared to larger needles and are also easier to manipulate. * use of suction: there is conflicting evidence in this point. several studies have evaluated the use of high volume aspiration vs low volume aspiration, continous aspiration vs no aspiration and suction with empty syringe vs water-filled syringe but none is clearly better than other. the investigators aim is to evaluate if the use of intermittent suction improves the diagnostic yield of pancreatic lesions compared to standard (continuous) suction. up to our knowledge this method has not been yet evaluated.

Eligibility criteria:
inclusion criteria: * pancreatic solid lesion * patients over 18 years old * suitable for endoscopy exclusion criteria: * contraindication for endoscopy * active anticoagulant therapy * thrombocytopenia or coagulopathy in the absence of its correction prior to the procedure * absence of informed consent * pregnancy * not accessible lesion for endoscopic ultrasound puncture

Keywords: pancreatic adenocarcinoma endoscopic ultrasound fine-needle aspiration
study of blu-808 in allergic rhinoconjunctivitis

Conditions: Allergic Rhinoconjunctivitis

Summary: this study will evaluate the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and preliminary clinical activity of blu-808 in participants with ragweed (ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (arc). participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (aec).


Eligibility criteria:
key inclusion criteria 1. adults, 18 years of age or older, willing to provide written informed consent, and willing to comply with all study requirements. 2. history (\>2 years) of ragweed-induced arc. 3. a positive ragweed skin prick test (mean diameter of ≥ 5 mm) in the last 6 months. 4. must meet clinically relevant nasal and ocular symptoms as defined by the protocol. key exclusion criteria participants are excluded from the study if any of the following criteria are met: 1. receiving medications (oral, nasal, topical, ocular, or injectable) to treat their ragweed or other allergy symptoms and/or receiving any medications that impact participants' safety or interfere with study assessments or interpretation of study results. 2. have active rhinitis, sinusitis, and/or other severe allergies not associated with the ragweed pollen that may interfere with study symptom assessments. 3. any prior or ongoing clinically significant illness, medical or psychiatric condition, surgical history, or physical finding that may interfere with the assessment or interpretation of study results. 4. clinically significant moderate to severe, uncontrolled cardiovascular, renal or hepatic disease. 5. significant bleeding risk or coagulation disorders. 6. any form of smoking, vaping or history of alcohol and drug abuse. 7. any malignancy within the past 5 years prior to screening/aec 1, except for basal cell or squamous cell carcinomas of the skin or carcinoma in situ. 8. inadequately controlled asthma that could affect the safety of the participant or interfere with the assessment or interpretation of study results. 9. known active/latent infection (viral, bacterial, fungal, helminth, or mycobacterial) such as tuberculosis, hepatitis b, hepatitis c, aids-related illness, or covid-19 infection. 10. history of sinonasal conditions that may confound the assessment or interpretation of study results.

Keywords: allergic rhinoconjunctivitis ambrosia artemisiifolia blu-808 ragweed
a phase 1 study to evaluate the pharmacokinetics and tolerability of oral azacitidine in japanese patients with myelodysplastic syndromes

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this study is to evaluate the tolerability of oral azacitidine in the treatment of patients with myelodysplastic syndromes (mds).


Eligibility criteria:
inclusion criteria: patients must satisfy the following criteria to be enrolled in the study: * have a documented diagnosis of myelodysplastic syndromes (mds) according to world health organization (who) 2008 classification * age ≥ 20 years; * written informed consent; * eastern cooperative oncology group (ecog) performance status of 0-2; * resolution of any toxic effects of prior anti-cancer therapy; and * negative urine or serum pregnancy test on females of childbearing potential. exclusion criteria: the presence of any of the following will exclude a patient from enrollment: * treatment with chemotherapy, radiotherapy, or surgery within 4 weeks of study registration; * pregnant or breast-feeding females; * previous or concomitant malignancy other than mds; * significant active cardiac disease within the previous 6 months; * uncontrolled systemic infection or * known infection with human immunodeficiency virus (hiv), hepatitis b, or hepatitis c
mental health and sexuality in adolescents and young adults

Conditions: Psychiatric Disorder; Adolescent Behavior; Mental Health Issue

Summary: according to the world health organization (who), "sexual health is a state of physical, emotional, mental and social well-being in relation to sexuality, not merely the absence of disease, dysfunction or of infirmity. sexual health requires a positive and respectful approach to sexuality and sexual relationships \[...\]". the main objective is to show that a training intervention intended for psychiatric care teams and targeted on the question of the impact of psychiatric disorders and psychotropic drugs on the sexuality of young people, increases the proportion of young people with whom the question of sexual health is discussed (in connection with psychiatric disorders and, if applicable, with the taking of psychotropic treatment, while they are hospitalized for a psychiatric disorder in the clinics of the fsef and receive, or not, psychotropic treatment ).

non-interventional multicenter prospective mixed study (quantitative and qualitative). research process in 3 phases: 1. inventory with a mixed method evaluation (quantitative survey and qualitative survey), * step 1: quantitative survey with self-administered questionnaire offered to all patients attending psychiatric study care during the month of the assessment. * step 2: qualitative survey of young people and caregivers. 2. design and implementation of an intervention adapted to the needs of the field (training for caregivers and tools for young people). * step 3: implementation of training programs for professionals based on data from phase 1 and preparation for interventions for young people. * step 4: interventions (interventions with young people in groups and individually). 3. reassessment after the deployment of the intervention - step 5: finally, the quantitative survey of stage 1 with a self-questionnaire offered to all patients present in psychiatric care-study will be repeated during one month of the evaluation in order to measure the impact of the action taken.

Eligibility criteria:
inclusion criteria: * young people hospitalized in psychiatric care-studies in one of the establishments of the fsef, * age ≥ 15 years (age of sexual majority), * receiving or not a psychotropic treatment, * no opposition to participation (or parents for minors) in the study and use of data exclusion criteria: * refusal to participate * patient under 15 years old * need for emergency care (medicine or psychiatry).

Keywords: psychotropic treatment sexuality teenagers and young adults
nefazodone in the treatment of social phobia

Conditions: Social Anxiety Disorder (SAD)

Summary: the purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (sad).

the purpose of this study is to examine the efficacy of the 5ht2 receptor antagonist nefazadone in sad, and to explore regional cerebral blood flow in patients with sad when confronted with a personal phobic stimulus, using positron emission tomography (pet). changes in cerebral blood flow were correlated with self-rated anxiety measures.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of generalized social anxiety disorder, males and females between the ages of 18-65 exclusion criteria: * a history of bipolar disorder, psychotic illness, or any other anxiety disorders, organic brain disease or active drug or alcohol abuse within one year as assessed by the scid-p and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. patients required to be free of psychotropic or beta-blocker medication for 2 weeks prior to study. pts taking fluoxetine required to be drug-free for 6 weeks.

Keywords: social anxiety disorder social phobia positron emission tomography (pet regional cerebral blood flow (rcbf) nefazodone amygdala
prevalence of bronchiectasis in copd patients

Conditions: Bronchiectasis; Chronic Obstruct Airways Disease; Prognosis

Summary: the identification of bronchiectasis in copd has been defined as a different clinical copd phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. a causal association has not yet been proven, but it is biologically plausible that copd, and particularly the infective and exacerbator copd phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

the relationship between bronchiectasis and copd has generated several questions. is there any real increased prevalence of bronchiectasis in patients with copd? does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in copd, to the extent that it can be considered a distinct clinical phenotype? should bronchiectasis in patients with copd be seen as merely a comorbidity, or as a consequence of the disease's natural history? is there a causal relationship between copd and bronchiectasis? if this is the case, what are the pathophysiological mechanisms responsible for this relationship? and, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Eligibility criteria:
inclusion criteria: * copd patients based on gold 2019 criteria, stable or in exacerbation exclusion criteria: * acute pneumonia within 2 months * malignancy * congenital bronchiectasis ( immobile cilia syndrome, kartagnar syndrome). * pregnancy

Keywords: bronchiectasis copd prevalence prognosis
a new surgical treatment technique "aspiration and percutaneous capsulotomy" for digital mucous cyst

Conditions: Digital Mucous Cyst

Summary: digital mucous cysts (dmcs) are a benign rubbery cystic lesion which usually involve the dorsal or lateral side of dip joint (digital interphalangeal joint) or proximal nail fold. the most successful treatment way is surgical management. however, which may cost time, require expertise, may cause infection, prolong wound healing and sometimes may lead to the joint movement limitation. the investigator bring this new technique: percutaneous capsulotomy for digital mucous cysts, which is easy and quick, last but not least, low recurrence rate.

participant between 2016 and 2017, 50 participants with dmcs in taipei veteran general hospital were included in this study. according to the clinical assessment at opd(out participants department), dmc was diagnosed. serial related serial clinical features of dmcs were investigated including participant's age, location, size of cysts, symptoms, duration, nail bed condition, underlying disease(ex. rheumatoid disease, diabetes) and previous treatment. after explaining to participants about the treatment choice (surgical excision, aspiration of cystic contents, and our needle assisted percutaneous capsulotomy for mucous cyst) and participants agreed with accepting needle assisted percutaneous capsulotomy, they were selected for accepting our needle assisted percutaneous capsulotomy for mucous cyst. surgical capsulotomy procedure. the surgical procedure for dmcs was using a 18g needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. all procedure were done with local anesthesia. after operation, the investigator asking participants using dressing to pressure the wound about 10 minutes to stop bleeding. later on, the wound was covering with antimicrobial ointment (neomycin) and simple dressing. educating participants from water for 24 hrs. clinical assessments the investigator evaluating participant's prognosis by vas, the improvement of fingernail deformity, the participants' subjective satisfaction and the recurrences was evaluating during follow-ups. this clinical study's approval was obtained from association of irb, taipei veteran general hospital.

Eligibility criteria:
inclusion criteria: * according to the clinical assessment at opd(out patient department), dmc was diagnosed. serial related serial clinical features of dmcs were investigated including pateint's age, location, size of cysts, symptoms, duration, nail bed condition, underlying disease(ex. rheumatoid disease, diabetes) and previous treatment exclusion criteria: * autoimmune disease related diffused arthritis, age younger than 20 year-old, severe painful deformity of the involved joint.

Keywords: digital mucous cyst capsulotomy
folic acid supplementation in calcific aortic valve disease

Conditions: Calcification of Aortic Valve; Aortic Valve Stenosis

Summary: this is a prospective, randomized, comparative, clinical trial conducted by wuhan union hospital that aims to evaluate the efficacy and safety of folic acid compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.

folic acid is involved in important physiological activities in the body such as dna synthesis, cell division and growth and development. recent studies have shown that folic acid may also have a positive effect on cardiovascular system health. aortic valve calcification is a cardiovascular disease whose incidence increases progressively with age. early studies suggest that folic acid may slow the progression of aortic valve calcification by inhibiting cell calcification and promoting calcium deposition. participants were randomized into two groups: one group was given oral folic acid treatment and the other group was given placebo control. patients in both groups were observed for aortic valve calcification during the follow-up period, and changes in aortic valve thickness, degree of calcification, and flow were recorded by cardiac ultrasonography, while the incidence of cardiovascular events and adverse effects were assessed.

Eligibility criteria:
inclusion criteria: * male or female adult ≥ 35 years of age at the time of recruiting. * subject has calcific aortic valve disease with mild to moderate aortic valve stenosis as defined by doppler echocardiography results: aortic valve mean pressure gradient between 10-30 mmhg and aortic valve area ≥ 1.2 and ≤ 2.0 cm2 on transthoracic echocardiography within 2 weeks prior to randomization and cardiac compute tomography (ct) test results: aortic valve calcium score (agatston score) ≥ 200 au at baseline cardiac ct within 1 month prior to randomization * subject provides written informed consent prior to initiation of any study procedures. * subject understands and agrees to comply with planned study procedures. exclusion criteria: * subject has concomitant moderate or severe mitral or tricuspid valve disease. * subject has left ventricular ejection fraction \< 50%. * subject previous history of aortic valve surgery, pancreatitis, malignant tumor, drug or alcohol abuse. * subjects whose alanine aminotransferase (alt) and aspartate aminotransferase (ast) \> 2.5 times the upper limit of normal range. * subjects who cannot undergo cardiac ct. * pregnant or lactating women. * consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment.

Keywords: folic acid calcification of aortic valve aortic valve stenosis
study to evaluate the remedy spectrum im spacer nail in the treatment of ankle-related infections

Conditions: Periprosthetic Joint Infection

Summary: this study is being conducted to evaluate the safety and effectiveness of the remedy spectrum im spacer nail in the treatment of ankle-related infections. the study is expected to take approximately 18 months from first subject enrolled to the last follow-up visit. it will have a 12-month enrollment period and a 6-month follow-up. this study is a prospective, multicenter, single-arm clinical trial. all subjects enrolled in this study will receive the remedy spectrum im spacer nail.


Eligibility criteria:
inclusion criteria: 1. be ≥ 21 years of age 2. have an ankle-related infection 3. is skeletally mature, as evidenced by closed epiphyses. 4. be able to give voluntary, written informed consent to participate and have signed an informed consent form specific to this study 5. be willing and able to comply with all study procedures including all pre-operative, post-operative requirements 6. if female and of child-bearing potential, must have a negative pregnancy test prior to the surgical procedure and no intention of becoming pregnant until study completion. exclusion criteria: 1. infections that do not involve the ankle 2. have a known immunodeficiency; including subjects who are receiving or have received immunosuppressants, immunostimulating agents or radiation therapy within 6 months prior to surgery 3. affected limb is dysvascular 4. where adequate soft-tissue coverage cannot be achieved 5. have any mental or psychological disorder that would impair their ability to complete the study questionnaires 6. are currently pregnant or breastfeeding, or planning to become pregnant or breastfeed any time during the course of the study 7. are currently a prisoner 8. have any medical condition or other circumstances, in the judgment of the investigator, that might interfere with the ability to return for follow-up visits, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative activities. 9. history of vancomycin or gentamicin allergy 10. are implanted with other antibiotic eluting products.

Keywords: ankle-related infections
prognostic factors and mortality in older stroke patients with mechanical thrombectomy

Conditions: Stroke, Ischemic

Summary: the study focus on the elderly patient (older than 80 years of age) who had acute ischemic stroke and received mechanical thrombectomy. the investigators analyze different factors in the stage of before, between, after procedure and trying to figure out if there is any difference between the 30-day-mortality group versus non-30-day-mortality group.

with the constant improvements in health care, standard of living and the decrease birth rate, the percentage of the elderly population ( above 80 years old) is expected to double in taiwan by the year 2044, according to data from the national development council. consequently with the increase in the proportion of senior citizens, there will be an surge number of patient suffering from cardiovascular and cerebrovascular diseases, most importantly acute ischemic stroke. in recent years, mechanical thrombectomy has become the gold standard in the treatment for acute stroke patients, however, many studies have excluded the patients above the age of 80 years old as the benefits of the procedure have been very controversial and there is no clear evidence proving favorable a outcome. there are a few studies which state that though elderly patients had higher risk of complications when receiving mechanical thrombectomy as compared to younger patients, the prognosis was still superior to those didn't receive any intervention. previous studies put more emphasis on the overall prognosis, morbidity and mortality rate, they didn't focused on the cause of mortality. the study focuses on analyzing of the cause of mortality and whether there is a significant difference between 30-day-mortality group versus non-30-day-mortality group.

Eligibility criteria:
inclusion criteria: 1. elderly (older than 80 years old) 2. acute ischemic stroke in anterior circulation 3. nihss more than 8 exclusion criteria: 1. posterior infarction 2. aspect score less than 3

Keywords: thrombectomy,acute ischemic stroke